ArticleAmerican journal of clinical pathology2014
Using the hemoglobin content of reticulocytes (RET-He) to evaluate anemia in patients with cancer.
Article in American journal of clinical pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Diagnostic accuracy of reticulocyte haemoglobin content in detecting iron deficiency without anaemia in blood donors: A systematic review and meta-analysis.Vox sanguinis · 2026Pooled it
- Delta-He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD-1/PD-L1 Inhibitors.Cancer medicine · 2025Article
- Utility of reticulocyte hemoglobin as a new predictor of anemia in intensive care unit patients.Frontiers in medicine · 2025Article
- Article
- Anemia diagnosis and therapy in malignant diseases: implementation of guidelines-a representative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Observational
- TAM-ing the CIA-Tumor-Associated Macrophages and Their Potential Role in Unintended Side Effects of Therapeutics for Cancer-Induced Anemia.Frontiers in oncology · 2021Article
- Article
- Diagnostic performance of reticulocyte hemoglobin equivalent in assessing the iron status.Journal of clinical laboratory analysis · 2020Article
- Review
- Evaluation of RET-He values as an early indicator of iron deficiency anemia in pregnant women.Hematology, transfusion and cell therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesEvaluation of anemia, particularly iron deficiency, in patients with cancer is difficult. This study examined using the hemoglobin content of reticulocytes (RET-He) to rule out iron deficiency, as defined by serum iron studies (transferrin saturation <20%, serum iron <40 μg/dL, and ferritin <100 ng/mL), in an unselected cancer patient population.
methodsPatients were entered into the study based on the existence of concurrent laboratory test requests for CBC and serum iron studies.
resultsUsing a threshold of 32 pg/cell, RET-He ruled out iron deficiency with a negative predictive value (NPV) of 98.5% and 100%, respectively, in the study population (n = 209) and in a subpopulation of patients with low reticulocyte counts (n = 19). In comparison, the NPV of traditional CBC parameters (hemoglobin, <11 g/dL; mean corpuscular volume, <80 fL) was only 88.5%.
conclusionsThese results support the use of RET-He in the evaluation of iron deficiency in a cancer care setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.